Recent Updates
Recently added Catalysts

NC-758

Phase 2

Stroke | Small molecule | Neurology |GSK plc|Last Updated: Jun 24, 2005

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment30
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00056238Cerebril™ in Patients With Lobar Hemorrhage Related to Cerebral Amyloid AngiopathyPHASE2 COMPLETED 30Feb 1, 2003 -Jun 24, 20055 United States
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
NC-758 (Anti amyloidotic [Aß] agent)DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range55 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria * Patients must be 55 years of age or older. * Males and females. Females must be of non-childbearing potential (i.e. surgically sterilized or at least one year post-menopausal). * Diagnosis of possible or probable CAA based on the Boston Criteria for Diagnosis of CAA-Related Hem...

Countries:United States
Unlock Eligibility Criteria